Index of reports
> Cases with Febrile Neutropenia (34)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Mesna where reactions include febrile neutropenia. The selected reports were submitted to the FDA during the sample period of about a year.
Reports 1 - 30 of 34 Next >>
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-07-18
Patient: female, weighing 13.1 kg (28.8 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
Indication: Sarcoma Metastatic
Vinorelbine Tartrate
Dosage: last dose prior to sae:20/jun/2012
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Doxorubicin Hydrochloride
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Cyclophosphamide
Dosage: last dose prior to sae 23/jun/2012
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Other drugs received by patient: Ondansetron; Levomepromazine; Moviprep; Fluconazole; Levomepromazine; Cotrim; Docusate; Ondansetron; Gentamicin; Morphine; Moviprep; Neupogen; Neupogen; Dihydrocodeine Bitartrate INJ; Acetaminophen; Ondansetron; Docusate; Docusate; Piperacillin and Tazobactam; Moviprep; Emollient Cream (Unk Ingredients); Ondansetron
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-07-13
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Vincristine and Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Avastin
Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Vinorelbine Tartrate
Dosage: last dose prior to sae:20/jun/2012
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Cyclophosphamide
Dosage: last dose prior to sae 23/jun/2012
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Ondansetron; Ondansetron; Gentamicin; Moviprep; Moviprep; Levomepromazine; Moviprep; Docusate; Cotrim; Docusate; Neupogen; Acetaminophen; Levomepromazine; Neupogen; Ondansetron; Piperacillin and Tazobactam; Dihydrocodeine Bitartrate INJ; Ondansetron; Fluconazole; Docusate; Morphine; Emollient Cream (Unk Ingredients)
Possible Mesna side effects in 46 year old male
Reported by a physician from United States on 2012-07-12
Patient: 46 year old male
Reactions: Febrile Neutropenia, Deep Vein Thrombosis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Rituxan
Dosage: 698 mg, unk
Start date: 2012-05-02
Mesna
Dosage: 1116 mg, unk
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 446 mg, unk
Doxorubicin HCL
Dosage: 56.5 mg, unk
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
End date: 2012-02-22
Pegfilgrastim
Dosage: 6 mg, unk
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Dosage: 630 mg, q12h
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
End date: 2012-02-22
Vincristine Sulfate
Dosage: 2 mg, unk
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
Doxorubicin HCL
Dosage: 37 mg, unk
Dexamethasone
Dosage: 40 mg, unk
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
Rituxan
Dosage: 787.5 mg, unk
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
End date: 2012-02-22
Other drugs received by patient: MS Contin; Valtrex; Omeprazole; Ciprofloxacin; Morphine Sulfate; Enoxaparin / 01708202 /; Compazine; Fluconazole; Metoprolol Tartrate
Possible Mesna side effects in 46 year old male
Reported by a physician from United States on 2012-07-09
Patient: 46 year old male
Reactions: Febrile Neutropenia, Deep Vein Thrombosis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
End date: 2012-02-22
Doxorubicin HCL
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
End date: 2012-02-22
Neulasta
Doxorubicin HCL
Vincristine
Neulasta
Indication: non-Hodgkin's Lymphoma
Mabthera
Start date: 2012-05-02
Mabthera
Indication: non-Hodgkin's Lymphoma
Start date: 2012-02-17
End date: 2012-02-22
Vincristine
Indication: non-Hodgkin's Lymphoma
Mesna
Cyclophosphamide
Dexamethasone
Administration route: Oral
Mesna
Indication: non-Hodgkin's Lymphoma
Dexamethasone
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Other drugs received by patient: Valtrex; Omeprazole; Fluconazole; Metoprolol; Morphine; Ciprofloxacin; MS Contin; Enoxaparin; Compazine
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-07-06
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Cyclophosphamide
Dosage: last dose prior to sae 23/jun/2012
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Vinorelbine Tartrate
Dosage: last dose prior to sae:20/jun/2012
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Avastin
Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Other drugs received by patient: Ondansetron; Neupogen; Dihydrocodeine Bitartrate INJ; Ondansetron; Fluconazole; Levomepromazine; Docusate; Piperacillin and Tazobactam; Cotrim; Gentamicin; Ondansetron; Morphine; Moviprep; Emollient Cream (Unk Ingredients); Ondansetron; Docusate; Moviprep; Neupogen; Acetaminophen; Levomepromazine; Moviprep; Docusate
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-07-02
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Vinorelbine Tartrate
Dosage: last dose prior to sae 08/may/2012
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Cyclophosphamide
Dosage: last dose prior to sae 06/06/2012
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Avastin
Dosage: frequency: day 1, last dose prior to sae: 21/05/2012
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Other drugs received by patient: Ondansetron; Levomepromazine; Moviprep; Moviprep; Cotrim; Morphine; Docusate; Docusate; Gentamicin; Moviprep; Emollient Cream (Unk Ingredients); Acetaminophen; Ondansetron; Ondansetron; Fluconazole; Levomepromazine; Piperacillin and Tazobactam; Ondansetron; Neupogen; Dihydrocodeine Bitartrate INJ; Docusate; Neupogen
Possible Mesna side effects in
Reported by a health professional (non-physician/pharmacist) from Croatia (Local Name: Hrvatska) on 2012-06-12
Patient:
Reactions: Mucosal Inflammation, Multi-Organ Failure, Tumour Lysis Syndrome, Condition Aggravated, Febrile Neutropenia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Methotrexate
Dosage: on day 1 with folinic acid rescue
Indication: Burkitt's Leukaemia
Methotrexate
Dosage: on day 1 with folinic acid rescue
Indication: Burkitt's Lymphoma
Cytarabine
Dosage: on days 4, 5
Indication: Burkitt's Leukaemia
Doxorubicin HCL
Dosage: on days 4, 5
Indication: Burkitt's Leukaemia
Cyclophosphamide
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Etoposide
Dosage: days 4, 5
Indication: Burkitt's Leukaemia
Leucovorin Calcium
Indication: Burkitt's Lymphoma
Cyclophosphamide
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Prednisone TAB
Dosage: days 1-5
Indication: Burkitt's Leukaemia
Dexamethasone
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Etoposide
Dosage: days 4, 5
Indication: Burkitt's Lymphoma
Rituximab
Indication: Burkitt's Leukaemia
Radiation Therapy NOS
Dosage: 30-36 gy
Indication: Burkitt's Leukaemia
Doxorubicin HCL
Dosage: on days 4, 5
Indication: Burkitt's Lymphoma
Prednisone TAB
Dosage: days 1-5
Indication: Burkitt's Lymphoma
Ifosfamide
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Prophylaxis
Methylprednisolone
Indication: Prophylaxis
Rituximab
Indication: Burkitt's Lymphoma
Cytarabine
Dosage: on days 4, 5
Indication: Burkitt's Lymphoma
Dexamethasone
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Leucovorin Calcium
Indication: Burkitt's Leukaemia
Radiation Therapy NOS
Dosage: 30-36 gy
Indication: Burkitt's Lymphoma
Vincristine
Dosage: on day 1
Indication: Burkitt's Leukaemia
Vincristine
Dosage: on day 1
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Prophylaxis
Mesna
Dosage: on days 1-5
Indication: Burkitt's Leukaemia
Mesna
Dosage: on days 1-5
Indication: Burkitt's Lymphoma
Other drugs received by patient: Blood Products; Acyclovir; Antibiotics; Neupogen
Possible Mesna side effects in female
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-06-06
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Mucosal Inflammation, Fungaemia, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Ifosfamide
Dosage: dadys 1 and 2
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Mesna
Start date: 2011-09-21
Mesna
Mesna
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Cyclophosphamide
Dosage: 11 mg
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Doxorubicin HCL
Dosage: days 1 and 2
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Dactinomycin
Dosage: day 1 of cycle
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Vincristine
Dosage: days 1, 8 and 15 of cycle
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Bevacizumab
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Navelbine
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Other drugs received by patient: Ondansetron; Ondansetron; Levomepromazine; Docusate; Gentamycin Sulfate; Piperacillin and Tazobactam; Ondansetron; Neupogen; Levomepromazine; Docusate; Fluconazole; Docusate; Dihydrocodeine Bitartrate INJ; Ondansetron; Movicol / 01625101 /; Movicol / 01625101 /; Neupogen; Acetaminophen; Morphine; Movicol / 01625101 /; Cotrim
Possible Mesna side effects in female
Reported by a physician from Italy on 2012-05-31
Patient: female, weighing 25.5 kg (56.1 pounds)
Reactions: Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Bevacizumab
Indication: Rhabdomyosarcoma
Start date: 2012-03-13
Vincristine
Indication: Rhabdomyosarcoma
Start date: 2012-03-13
Dactinomycin
Start date: 2012-04-04
Bevacizumab
Start date: 2012-04-04
Mesna
Indication: Rhabdomyosarcoma
Start date: 2012-03-13
Vincristine
Start date: 2012-04-04
Dactinomycin
Indication: Rhabdomyosarcoma
Start date: 2012-03-13
Ifosfamide
Indication: Rhabdomyosarcoma
Start date: 2012-03-13
Ifosfamide
Start date: 2012-04-04
Mesna
Start date: 2012-04-04
Doxorubicin HCL
Indication: Rhabdomyosarcoma
Start date: 2012-03-13
Other drugs received by patient: Cotrim; Acetaminophen; Mycostatin; Bactrim
Possible Mesna side effects in female
Reported by a individual with unspecified qualification from United Kingdom on 2012-05-29
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Vinorelbine Tartrate
Dosage: last dose prior to sae 08/may/2012
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Avastin
Dosage: frequency: day 1, last dose prior to sae: 08/jul/2012
Indication: Sarcoma Metastatic
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Cyclophosphamide
Dosage: last dose prior to sae 11/may/2012
Administration route: Oral
Indication: Rhabdomyosarcoma
Start date: 2012-03-01
Other drugs received by patient: Fluconazole; Acetaminophen; Docusate; Emollient Cream (Unk Ingredients); Ondansetron; Ondansetron; Docusate; Morphine; Moviprep; Moviprep; Neupogen; Gentamicin; Moviprep; Ondansetron; Levomepromazine; Cotrim; Neupogen; Ondansetron; Levomepromazine; Piperacillin and Tazobactam; Dihydrocodeine Bitartrate INJ; Docusate
Possible Mesna side effects in 18 year old female
Reported by a health professional (non-physician/pharmacist) from France on 2012-05-28
Patient: 18 year old female
Reactions: Oligohydramnios, Normal Newborn, Anaemia, Febrile Neutropenia, Neutropenia, Pregnancy, Thrombocytopenia
Drug(s) suspected as cause:
Neupogen
Indication: Rhabdomyosarcoma
Dactinomycin
Dosage: q21d
Indication: Rhabdomyosarcoma
Vincristine
Indication: Rhabdomyosarcoma
Cyclophosphamide
Dosage: 1 df: 2.2g/m2
Indication: Rhabdomyosarcoma
Mesna
Indication: Rhabdomyosarcoma
Possible Mesna side effects in 31 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-28
Patient: 31 year old female
Reactions: Oligohydramnios, Vomiting, Live Birth, Febrile Neutropenia, Erosive Oesophagitis, Pregnancy
Drug(s) suspected as cause:
Ifosfamide
Dosage: 1df= 5g/m3
Indication: Burkitt's Lymphoma
Vincristine
Indication: Burkitt's Lymphoma
Etoposide
Indication: Burkitt's Lymphoma
Neupogen
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Indication: Burkitt's Lymphoma
Cyclophosphamide
Indication: Burkitt's Lymphoma
Mesna
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Burkitt's Lymphoma
Rituximab
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Burkitt's Lymphoma
Leucovorin Calcium
Indication: Burkitt's Lymphoma
Possible Mesna side effects in 48 year old female
Reported by a consumer/non-health professional from United States on 2012-05-08
Patient: 48 year old female, weighing 55.0 kg (121.0 pounds)
Reactions: Blood Bilirubin Increased, Pneumonia Fungal, Soft Tissue Infection, Alanine Aminotransferase Increased, Febrile Neutropenia, Bronchitis, Neutrophil Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Dosage: last dose on 07dec11
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Methotrexate
Dosage: last:28jan2011,20mar12 courses:6 also taken 12mg(last dose on 06dec11)
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Vincristine Sulfate
Dosage: last dose on 8dec11 received 4dose on dec8
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Cyclophosphamide
Dosage: last dose on 07dec2011
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Doxorubicin HCL
Dosage: last dose on 08dec2011
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Cytarabine
Dosage: also taken 100mg(last12dec2011) last dose:31dec11,23mar12 courses:6
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Leucovorin Calcium
Dosage: last dose on 30dec11,22mar12 courses:6
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Sprycel
Dosage: dose held d5 d6,7 8 also taken 600mg (last11jan2012) last dose on 14dec2011,5apr12 courses:6
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Methylprednisolone
Dosage: last dose:21mar12 courses:6
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Dexamethasone
Dosage: last dose on 08dec2011
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Possible Mesna side effects in male
Reported by a individual with unspecified qualification from United Kingdom on 2012-05-07
Patient: male, weighing 49.0 kg (107.8 pounds)
Reactions: Febrile Neutropenia, Ingrowing Nail, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Ifosfamide
Start date: 2011-09-24
Ifosfamide
Start date: 2011-11-04
Ifosfamide
Start date: 2011-11-25
Vincristine
Start date: 2011-11-04
Vincristine
Start date: 2011-09-24
Bevacizumab
Start date: 2011-09-24
End date: 2011-09-24
Bevacizumab
Start date: 2011-11-25
Dactinomycin
Start date: 2011-09-24
Dactinomycin
Start date: 2011-11-04
Dactinomycin
Start date: 2011-11-25
Mesna
Start date: 2011-11-04
Doxorubicin HCL
Start date: 2011-11-25
Doxorubicin HCL
Start date: 2011-11-04
Bevacizumab
Start date: 2011-11-04
Doxorubicin HCL
Start date: 2011-09-24
Vincristine
Start date: 2011-11-25
Other drugs received by patient: Melatonin; Hyoscine HBR HYT; MST / 00036302 /; Metoclopramide; Cavilon; Acetaminophen; Acetaminophen; Movicol / 01625101 /; Ondansetron; Ondansetron; Movicol / 01625101 /; Docusate Sodium; Metoclopramide
Possible Mesna side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-13
Patient:
Reactions: Stomatitis, Haemoglobin Abnormal, Febrile Neutropenia, Platelet Disorder, Mucosal Inflammation, Diarrhoea, Colitis, Enteritis, Granulocytes Abnormal, Infection
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Neuroblastoma
Topotecan
Dosage: 0.04 mg/kg/day
Indication: Neuroblastoma
Etoposide
Dosage: 6.67 mg/kg/day
Vincristine
Dosage: 0.22 mg/kg/day
Cyclophosphamide
Dosage: 70 mg/kg/day
Doxorubicin HCL
Cyclophosphamide
Dosage: 13.3 mg/kg/day
Cyclophosphamide
Etoposide
Dosage: 6.67 mg/kg/day
Vincristine
Dosage: 0.22 mg/kg/day
Indication: Neuroblastoma
Vincristine
Dosage: 0.22 mg/kg/day
Cyclophosphamide
Dosage: 70 mg/kg/day
Cyclophosphamide
Topotecan
Dosage: 0.04 mg/kg/day
Cisplatin
Dosage: 1.66 mg/kg/day
Mesna
Dosage: 14 mg/kg/day
Cyclophosphamide
Dosage: 70 mg/kg/day
Cyclophosphamide
Topotecan
Dosage: 0.04 mg/kg/day
Cisplatin
Dosage: 1.66 mg/kg/day
Vincristine
Dosage: 0.22 mg/kg/day
Vincristine
Dosage: 0.22 mg/kg/day
Neupogen
Indication: Neutrophil Count
Cyclophosphamide
Dosage: 70 mg/kg/day
Topotecan
Dosage: 0.04 mg/kg/day
Mesna
Dosage: 14 mg/kg/day
Mesna
Dosage: 14 mg/kg/day
Mesna
Dosage: 14 mg/kg/day
Doxorubicin HCL
Dosage: 0.83 mg/kg/day
Indication: Neuroblastoma
Doxorubicin HCL
Topotecan
Dosage: 0.04 mg/kg/day
Cisplatin
Dosage: 1.66 mg/kg/day
Indication: Neuroblastoma
Cisplatin
Dosage: 1.66 mg/kg/day
Etoposide
Dosage: 6.67 mg/kg/day
Cyclophosphamide
Dosage: 70 mg/kg/day
Doxorubicin HCL
Cyclophosphamide
Cisplatin
Cisplatin
Etoposide
Dosage: 6.67 mg/kg/day
Indication: Neuroblastoma
Etoposide
Dosage: 6.67 mg/kg/day
Etoposide
Dosage: 6.67 mg/kg/day
Mesna
Dosage: 14 mg/kg/day
Indication: Neuroblastoma
Mesna
Dosage: 14 mg/kg/day
Vincristine
Dosage: 0.22 mg/kg/day
Cyclophosphamide
Dosage: 70 mg/kg/day
Doxorubicin HCL
Doxorubicin HCL
Topotecan
Dosage: 0.04 mg/kg/day
Possible Mesna side effects in 48 year old female
Reported by a consumer/non-health professional from United States on 2012-02-18
Patient: 48 year old female, weighing 55.0 kg (121.0 pounds)
Reactions: Blood Bilirubin Increased, Alanine Aminotransferase Increased, Febrile Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Sprycel
Dosage: dose held d5 d6,7 8 also taken 600mg (last11jan2012) last dose on 14dec2011
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Methotrexate
Dosage: last:28jan2011 also taken 12mg(last dose on 06dec11)
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Doxorubicin HCL
Dosage: last dose on 08dec2011
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Dexamethasone
Dosage: last dose on 08dec2011
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Leucovorin Calcium
Dosage: last dose on 30dec11
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Vincristine Sulfate
Dosage: last dose on 8dec11 received 4dose on dec8
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Cyclophosphamide
Dosage: last dose on 07dec2011
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Cytarabine
Dosage: also taken 100mg(last12dec2011) last dose:31dec11
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Mesna
Dosage: last dose on 07dec11
Indication: Acute Lymphocytic Leukaemia
Start date: 2011-12-05
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-02-14
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Other drugs received by patient: Ondansetron; Ondansetron; Fluconazole; Levomepromazine; Docusate; Docusate; Morphine; Neupogen; Emollient Cream (Unk Ingredients); Levomepromazine; Docusate; Neupogen; Ondansetron; Moviprep; Moviprep; Piperacillin and Tazobactam; Ondansetron; Paracetamol; Cotrim; Gentamicin; Dihydrocodeine Bitartrate INJ
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2012-01-18
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Other drugs received by patient: Acetaminophen; Ondansetron; Moviprep; Neupogen; Levomepromazine; Levomepromazine; Gentamicin; Emollient Cream (Unk Ingredients); Docusate; Piperacillin and Tazobactam; Morphine; Ondansetron; Neupogen; Ondansetron; Docusate; Moviprep; Ondansetron; Fluconazole; Docusate; Cotrim; Dihydrocodeine Bitartrate INJ
Possible Mesna side effects in female
Reported by a individual with unspecified qualification from United Kingdom on 2012-01-12
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, RED Blood Cell Count Decreased, Febrile Neutropenia, Platelet Count Decreased, Blood Sodium Decreased, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Doxorubicin Hydrochloride
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Levomepromazine; Levomepromazine; Docusate; Piperacillin and Tazobactam; Moviprep; Ondansetron; Neupogen; Neupogen; Cotrim; Ondansetron; Docusate; Docusate; Gentamicin; Dihydrocodeine Bitartrate INJ; Ondansetron; Fluconazole; Morphine; Acetaminophen; Ondansetron; Moviprep; Emollient Cream (Unk Ingredients)
Possible Mesna side effects in female
Reported by a individual with unspecified qualification from United Kingdom on 2012-01-10
Patient: female, weighing 12.9 kg (28.4 pounds)
Reactions: Haemoglobin Decreased, Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Blood Creatinine Increased, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Morphine; Moviprep; Ondansetron; Cotrim; Moviprep; Emollient Cream (Unk Ingredients); Dihydrocodeine Bitartrate INJ; Acetaminophen; Piperacillin and Tazobactam; Ondansetron; Fluconazole; Neupogen; Ondansetron; Docusate; Docusate; Neupogen; Ondansetron; Levomepromazine; Levomepromazine; Docusate; Gentamicin
Possible Mesna side effects in 18 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-01-05
Patient: 18 year old male
Reactions: Lung Infection, Hypotension, Febrile Neutropenia, Hypokalaemia
Drug(s) suspected as cause:
Methotrexate
Etoposide
Ifosfamide
Cisplatin
Mesna
Doxorubicin HCL
Possible Mesna side effects in 32 month old female
Reported by a consumer/non-health professional from United Kingdom on 2011-12-12
Patient: 32 month old female, weighing 12.0 kg (26.4 pounds)
Reactions: Fungaemia, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Ifosfamide
Start date: 2011-07-12
Ifosfamide
Start date: 2011-07-12
Mesna
Start date: 2011-07-12
Vincristine Sulfate
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Mesna
Start date: 2011-07-12
Dactinomycin
Start date: 2011-07-12
Mesna
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Ifosfamide
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Bevacizumab
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Doxorubicin HCL
Start date: 2011-07-12
Dactinomycin
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Vincristine Sulfate
Start date: 2011-07-12
Doxorubicin HCL
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Dactinomycin
Start date: 2011-07-12
Mesna
Start date: 2011-07-12
Other drugs received by patient: Ondansetron; Acetaminophen; Levomepromazine; Docusate; Moviprep; Fluconazole; Emollients and Protectives; Moviprep; Ondansetron; Cotrim
Possible Mesna side effects in female
Reported by a individual with unspecified qualification from United Kingdom on 2011-12-08
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Other drugs received by patient: Acetaminophen; Cotrim; Moviprep; Docusate; Piperacillin and Tazobactam; Dihydrocodeine Bitartrate INJ; Morphine; Gentamicin; Neupogen; Emollient Cream (Unk Ingredients); Docusate; Neupogen; Ondansetron; Fluconazole; Levomepromazine; Levomepromazine; Ondansetron; Ondansetron; Ondansetron; Moviprep
Possible Mesna side effects in female
Reported by a individual with unspecified qualification from United Kingdom on 2011-12-07
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Mesna
Dosage: date of last dose prior to sae: 21 sep 2011
Dactinomycin
Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
Start date: 2011-07-12
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Fluconazole; Piperacillin and Tazobactam; Ondansetron HCL; Ondansetron HCL; Moviprep; Ondansetron HCL; Docusate; Neupogen; Emollient Cream (Unk Ingredients); Acetaminophen; Levomepromazine; Levomepromazine; Cotrim; Ondansetron HCL; Docusate; Moviprep; Dihydrocodeine Bitartrate INJ; Gentamicin; Morphine; Neupogen
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2011-12-05
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Acetaminophen; Emollient Cream (Unk Ingredients); Cotrim; Piperacillin and Tazobactam; Moviprep; Levomepromazine; Docusate; Gentamicin; Neupogen; Fluconazole; Ondansetron; Morphine; Ondansetron; Moviprep
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2011-11-29
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
Indication: Sarcoma Metastatic
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Other drugs received by patient: Ondansetron; Neupogen; Ondansetron; Fluconazole; Piperacillin and Tazobactam; Morphine; Moviprep; Emollient Cream (Unk Ingredients); Paracetamol; Cotrim; Gentamicin; Moviprep; Docusate; Levomepromazine
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2011-11-14
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior tosae: 30 august 2011
Indication: Sarcoma Metastatic
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Other drugs received by patient: Ondansetron; Docusate; Moviprep; Acetaminophen; Cotrim; Morphine; Emollient Cream (Unk Ingredients); Levomepromazine; Piperacillin and Tazobactam; Fluconazole; Gentamicin; Ondansetron; Moviprep; Neupogen
Possible Mesna side effects in female
Reported by a physician from United Kingdom on 2011-11-11
Patient: female, weighing 12.7 kg (27.9 pounds)
Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dactinomycin
Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
Indication: Sarcoma Metastatic
Avastin
Dosage: frequency: day 1, last dose prior tosae: 30 august 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: od, dosage form: 3600 mg/m2
Doxorubicin HCL
Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Dactinomycin
Dosage: date of last dose prior to onset of sae: 11 oct 2011
Ifosfamide
Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Vincristine
Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
Indication: Sarcoma Metastatic
Mesna
Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
Indication: Sarcoma Metastatic
Other drugs received by patient: Gentamicin; Levomepromazine; Moviprep; Emollient Cream (Unk Ingredients); Acetaminophen; Ondansetron; Moviprep; Fluconazole; Cotrim; Ondansetron; Docusate; Morphine; Neupogen; Piperacillin and Tazobactam
Possible Mesna side effects in 19 year old male
Reported by a physician from United States on 2011-11-09
Patient: 19 year old male, weighing 65.8 kg (144.8 pounds)
Reactions: Hypotension, Lung Infection, Febrile Neutropenia, Hypokalaemia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Start date: 2011-10-13
Ifosfamide
Indication: Bone Sarcoma
Start date: 2011-10-13
End date: 2011-10-17
Methotrexate
Start date: 2011-10-13
Mesna
Start date: 2011-10-13
End date: 2011-10-17
Doxorubicin HCL
Indication: Bone Sarcoma
Start date: 2011-06-03
Etoposide
Start date: 2011-06-03
Ifosfamide
Start date: 2011-06-03
Cisplatin
Indication: Bone Sarcoma
Start date: 2011-06-03
Mesna
Indication: Bone Sarcoma
Start date: 2011-06-03
Methotrexate
Indication: Bone Sarcoma
Start date: 2011-06-03
Etoposide
Indication: Bone Sarcoma
Start date: 2011-10-13
End date: 2011-10-17
Cisplatin
Start date: 2011-10-13
Possible Mesna side effects in 32 month old female
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2011-10-27
Patient: 32 month old female, weighing 11.0 kg (24.2 pounds)
Reactions: Fungaemia, Mucosal Inflammation, Febrile Neutropenia, Epistaxis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Ifosfamide
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Mesna
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Doxorubicin HCL
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Ifosfamide
Start date: 2011-07-12
Vincristine Sulfate
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Dactinomycin
Start date: 2011-07-12
Mesna
Start date: 2011-07-12
Mesna
Start date: 2011-07-12
Doxorubicin HCL
Start date: 2011-07-12
Bevacizumab
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Dactinomycin
Indication: Sarcoma Metastatic
Start date: 2011-07-12
Other drugs received by patient: Ondansetron; Levomepromazine; Cotrim; Acetaminophen; Moviprep; Moviprep; Docusate; Fluconazole
Page 1 Next >>
|